Overdiagnosis in Cancer

被引:1206
作者
Welch, H. Gilbert [1 ,2 ,3 ]
Black, William C. [3 ,4 ]
机构
[1] Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, White River Jct, VT 05009 USA
[2] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice,Dept M, Hanover, NH 03756 USA
[3] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice,Dept C, Hanover, NH 03756 USA
[4] Dartmouth Hitchcock Med Ctr, Dept Radiol, Lebanon, NH 03766 USA
关键词
COMPUTED-TOMOGRAPHY SCANNER; MAYO LUNG PROJECT; PROSTATE-CANCER; MELANOMA EPIDEMIC; SCREENING TRIAL; BREAST-CANCER; ADRENAL MASS; FOLLOW-UP; NEUROBLASTOMA; RATES;
D O I
10.1093/jnci/djq099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This article summarizes the phenomenon of cancer overdiagnosis-the diagnosis of a "cancer" that would otherwise not go on to cause symptoms or death. We describe the two prerequisites for cancer overdiagnosis to occur: the existence of a silent disease reservoir and activities leading to its detection (particularly cancer screening). We estimated the magnitude of overdiagnosis from randomized trials: about 25% of mammographically detected breast cancers, 50% of chest x-ray and/or sputum-detected lung cancers, and 60% of prostate-specific antigen-detected prostate cancers. We also review data from observational studies and population-based cancer statistics suggesting overdiagnosis in computed tomography-detected lung cancer, neuroblastoma, thyroid cancer, melanoma, and kidney cancer. To address the problem, patients must be adequately informed of the nature and the magnitude of the trade-off involved with early cancer detection. Equally important, researchers need to work to develop better estimates of the magnitude of overdiagnosis and develop clinical strategies to help minimize it.
引用
收藏
页码:605 / 613
页数:9
相关论文
共 46 条
[1]   Mortality Results from a Randomized Prostate-Cancer Screening Trial [J].
Andriole, Gerald L. ;
Grubb, Robert L., III ;
Buys, Saundra S. ;
Chia, David ;
Church, Timothy R. ;
Fouad, Mona N. ;
Gelmann, Edward P. ;
Kvale, Paul A. ;
Reding, Douglas J. ;
Weissfeld, Joel L. ;
Yokochi, Lance A. ;
Crawford, E. David ;
O'Brien, Barbara ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hayes, Richard B. ;
Kramer, Barnett S. ;
Izmirlian, Grant ;
Miller, Anthony B. ;
Pinsky, Paul F. ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1310-1319
[2]  
[Anonymous], 2006, SEER cancer statistics review, 1975-2003
[3]   The melanoma epidemic:: Res ipsa loquitur [J].
Beddingfield, FC .
ONCOLOGIST, 2003, 8 (05) :459-465
[4]  
Berland Lincoln L, 2009, J Am Coll Radiol, V6, P14, DOI 10.1016/j.jacr.2008.06.018
[5]  
Bessho F, 1996, INT J CANCER, V67, P520, DOI 10.1002/(SICI)1097-0215(19960807)67:4<520::AID-IJC10>3.0.CO
[6]  
2-B
[7]   Where should neuroblastoma mass screening go? [J].
Bessho, F .
LANCET, 1996, 348 (9043) :1672-1672
[8]   Clinicopathologic features of prostate adenocarcinorna incidentally discovered at the time of radical cystectomy: An evidence-based analysis [J].
Damiano, Rocco ;
Di Lorenzo, Giuseppe ;
Cantiello, Francesco ;
De Sio, Marco ;
Perdona, Sisto ;
D'Armiento, Massimo ;
Autorino, Riccardo .
EUROPEAN UROLOGY, 2007, 52 (03) :648-657
[9]   Increasing incidence of thyroid cancer in the United States, 1973-2002 [J].
Davies, L ;
Welch, HG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (18) :2164-2167
[10]   Analysis of the melanoma epidemic, both apparent and real - Data from the 1973 through 1994 surveillance, epidemiology, and end results program registry [J].
Dennis, LK .
ARCHIVES OF DERMATOLOGY, 1999, 135 (03) :275-280